ArticleRevista peruana de medicina experimental y salud publica2026
Clinical and microbiological characteristics of neonates with bacteremia by NDM-producing Klebsiella pneumoniae in a Peruvian referral hospital.
Article in Revista peruana de medicina experimental y salud publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted a descriptive cross-sectional study in the neonatology service of the Hospital Nacional Guillermo Almenara Irigoyen (2020-2024) to characterize the clinical and microbiological profile of neonates with carbapenemase-producing Klebsiella pneumoniae bacteremia. Nineteen neonates were included; most were preterm and low birth weight, and approximately half presented bacteremia secondary to a respiratory focus. All strains carried the blaNDM gene. In vitro, 84.2% (16/19) were susceptible to amikacin and 40% (6/15) to tigecycline. All isolates had intermediate susceptibility to colistin and resistance to multiple antimicrobials. Empirical therapy was appropriate in 7/16 (43.8%) and about a fifth of the patients died. The identification of blaNDM reinforces the importance of local genomic surveillance to guide empirical therapy. The type of carbapenemase and its impact on mortality is a future research gap.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.